<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1812-9528</journal-id>
<journal-title><![CDATA[Memorias del Instituto de Investigaciones en Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Mem. Inst. Investig. Cienc. Salud]]></abbrev-journal-title>
<issn>1812-9528</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Investigaciones en Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1812-95282020000200047</article-id>
<article-id pub-id-type="doi">10.18004/mem.iics/1812-9528/2020.018.02.47</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Anticoagulación oral y riesgo de sangrado en pacientes con fibrilación auricular no valvular del Hospital Militar Central]]></article-title>
<article-title xml:lang="en"><![CDATA[Oral anticoagulation and bleeding risk in patients with non-valvular atrial fibrillation of the Central Military Hospital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz-Galeano]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fleitas-Halaburda]]></surname>
<given-names><![CDATA[Néstor Elías]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Boccia-Paz]]></surname>
<given-names><![CDATA[Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arrúa-Torreani]]></surname>
<given-names><![CDATA[Néstor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Ciencias Médicas Hospital de Clínicas]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Militar Central Servicio de Clínica Médica ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<volume>18</volume>
<numero>2</numero>
<fpage>47</fpage>
<lpage>53</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1812-95282020000200047&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1812-95282020000200047&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1812-95282020000200047&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La fibrilación auricular es la arritmia más frecuente y puede causar accidente cerebrovascular. El objetivo de este estudio fue determinar el tipo de anticoagulante oral recibido y el riesgo de sangrado en pacientes con fibrilación auricular no valvular del Hospital Militar Central. El estudio, descriptivo, retrospectivo de corte transversal, incluyó a pacientes adultos con diagnóstico de fibrilación auricular no valvular del Hospital Militar Central desde enero de 2015 a agosto de 2018. Se determinaron las variables demográficas, diagnóstico de fibrilación auricular valvular y no valvular, tipo de anticoagulación oral recibida, escala de ictus (CHA2DS2-VASc) y de hemorragia (HAS-BLED), control de anticoagulación con el INR y adherencia al tratamiento anticoagulante. Se incluyeron 220 pacientes con fibrilación auricular, 60% presentó fibrilación auricular no valvular, edad media de 71±4,6 años, y el 57,8% fueron hombres. Recibieron anticoagulación oral 79% de los pacientes, de los cuales el 80% recibió anticoagulante anti vitamina K. El promedio de puntos en la escala de CHA2DS2-VASc fue de 3,5 puntos y en la escala de HAS-BLED el promedio de puntos obtenidos fue de 1,9 y los factores de riesgo más comunes de sangrado fueron la HTA y edad mayor a 65 años. En este estudio se encontró que la mayoría de los pacientes con FANV fueron anticoagulados, tenían alta adherencia al tratamiento y buen control de la ancoagulación. El anticoagulante oral más utilizado fue el anti vitamina K, hubo riesgo intermedio para el sangrado y los factores de riesgo de sangrado más comunes fueron la hipertensión arterial y la edad &gt;65 años.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Atrial fibrillation is the most frequent arrhythmia and can cause stroke. The objective of this study was to determine the type of oral anticoagulant received and the risk of bleeding in patients with non-valvular atrial fibrillation of the Central Military Hospital. The descriptive, retrospective cross-sectional study, included adult patients with a diagnosis of non-valvular atrial fibrillation from the Central Military Hospital from January 2015 to August 2018. Demographic variables, diagnosis of valvular and non-valvular atrial fibrillation, type of oral anticoagulation received, stroke scale (CHA2DS2-VASc), hemorrhage (HAS-BLED) scale, control of anticoagulation with the INR and adherence to anticoagulant treatment were determined. Two hundred and twenty patients with atrial fibrillation were included, 60% presented non-valvular atrial fibrillation, mean age of 71±4.6 years and 57.8% were men. Seventy nine percent of the patients received oral anticoagulation, of which 80% received anti-vitamin K anticoagulant. The average point on the CHA2DS2-VASc scale was 3.5 point and on the HAS-BLED scale the average point obtained was of 1.9 while the most common risk factors for bleeding were AHT and age over 65 years. In this study, it was found that the majority of patients with FANV was anticoagulated, had a high adherence to treatment, and good control of ancoagulation. The most widely used oral anticoagulant was anti vitamin K, intermediate risk for bleeding and risk factors for bleeding, the most common was arterial hypertension and age&gt;65 years.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[anticoagulación]]></kwd>
<kwd lng="es"><![CDATA[accidente cerebrovascular]]></kwd>
<kwd lng="es"><![CDATA[hipertensión]]></kwd>
<kwd lng="en"><![CDATA[atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[anticoagulation]]></kwd>
<kwd lng="en"><![CDATA[stroke]]></kwd>
<kwd lng="en"><![CDATA[hypertension]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deshpande]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Catanzaro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial Fibrillation Prevalence and Scope of the Problem]]></article-title>
<source><![CDATA[Card Electrophysiol Clin. marzo de]]></source>
<year>2014</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[Prevalencia de fibrilación auricular en pacientes hospitalizados por Medicina interna - Science Direct]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Moraes]]></surname>
<given-names><![CDATA[ERFL]]></given-names>
</name>
<name>
<surname><![CDATA[Cirenza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Guimaraes]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[AAE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting]]></article-title>
<source><![CDATA[Eur J Intern Med. septiembre de]]></source>
<year>2019</year>
<volume>67</volume>
<page-range>36-41</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Witkowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bissinger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grycewicz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lubinski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asymptomatic atrial fibrillation in patients with atrial fibrillation and implanted pacemaker]]></article-title>
<source><![CDATA[Int J Cardiol. 15 de enero de]]></source>
<year>2017</year>
<volume>227</volume>
<page-range>583-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perera]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Hohnloser]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stroke type and severity in patients with subclinical atrial fibrillation An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT)]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2018</year>
<volume>201</volume>
<page-range>160-3</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<source><![CDATA[fibrillation of Paraguay hospital interior]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<source><![CDATA[ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS - PubMed]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YG]]></given-names>
</name>
<name>
<surname><![CDATA[Shim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boo]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Different influence of cardiac hemodynamics on thromboembolic events in patients with paroxysmal and non-paroxysmal atrial fibrillation]]></article-title>
<source><![CDATA[PloS One]]></source>
<year>2019</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavallari]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ruff]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Nordio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Deenadayalu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lanz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical events after interruption of anticoagulation in patients with atrial fibrillation An analysis from the ENGAGE AF-TIMI 48 trial]]></article-title>
<source><![CDATA[Int J Cardiol. 15 de]]></source>
<year>2018</year>
<volume>257</volume>
<page-range>102-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerra García]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valladares Carvajal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal Valladares]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Quiñones]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo asociados a ictus cardioembólico en pacientes con fibrilación auricular no valvular]]></article-title>
<source><![CDATA[Rev Finlay. marzo de]]></source>
<year>2018</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-17</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mentias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shantha]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Adeola]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Narasimhan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Siontis]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation A Medicare analysis]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2019</year>
<volume>214</volume>
<page-range>158-66</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<source><![CDATA[Guidelines for the Management of Atrial Fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) - PubMed]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilyarov]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Konstantinova]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Trukhin]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current possibilities of anticoagulant therapy in patients with atrial fibrillation]]></article-title>
<source><![CDATA[Klinicist. 1 de enero de]]></source>
<year>2015</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>15-21</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogilvie]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Welner]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Cowell]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Underuse of oral anticoagulants in atrial fibrillation: a systematic review]]></article-title>
<source><![CDATA[Am J Med.]]></source>
<year>2010</year>
<volume>123</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>638-45</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New-onset atrial fibrillation and warfarin initiation high risk periods and implications for new antithrombotic drugs]]></article-title>
<source><![CDATA[Thromb Haemost. diciembre de]]></source>
<year>2010</year>
<volume>104</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1099-105</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
<name>
<surname><![CDATA[Andreotti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fauchier]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bleeding risk assessment and management in atrial fibrillation patients a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis]]></article-title>
<source><![CDATA[Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. mayo de]]></source>
<year>2011</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>723-46</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilera Alcaraz]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Abellán Huerta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carbayo Herencia]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ariza Copado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Menárguez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Abellán Alemán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valoración del tratamiento anticoagulante en pacientes diagnosticados de fibrilación auricular no valvular en una zona básica de salud]]></article-title>
<source><![CDATA[Clínica E Investig En Arterioscler. 1 de marzo de]]></source>
<year>2018</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>56-63</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bustos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ocampo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrero]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vergara]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad y seguridad del tratamiento anticoagulante con acenocumarol en fibrilación auricular no valvular]]></article-title>
<source><![CDATA[Rev Médica Chile. octubre de]]></source>
<year>2017</year>
<volume>145</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1243-51</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wojszel]]></surname>
<given-names><![CDATA[ZB]]></given-names>
</name>
<name>
<surname><![CDATA[Kasiukiewicz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Swietek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Swietek]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Magnuszewski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CHA2DS2-VASc score can guide the screening of atrial fibrillation - cross-sectional study in a geriatric ward]]></article-title>
<source><![CDATA[Clin Interv Aging]]></source>
<year>2019</year>
<volume>14</volume>
<page-range>879-87</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mora-Llabata]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dubois-Marqués]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán-Torres]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mateu-Navarro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sanz-García]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Ballester]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de fibrilación auricular y características de la fibrilación auricular no valvular en la población general Registro AFINVA]]></article-title>
<source><![CDATA[Rev Colomb Cardiol. febrero de]]></source>
<year>2017</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-33</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Etiología y prevención de la fibrilación auricular]]></article-title>
<source><![CDATA[Revista Española de Cardiología]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linares]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Armas]]></surname>
<given-names><![CDATA[LAS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de la anticoagulación en fibrilación auricular no reumática para profilaxis de accidentes cerebrovasculares]]></article-title>
<source><![CDATA[Rev Cuba Med. 30 de junio de]]></source>
<year>2015</year>
<volume>54</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>129-38</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la Figuera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cinza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Egocheaga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil clínico de pacientes con fibrilación auricular tratados con anticoagulantes orales de acción directa atendidos en atención primaria Estudio SILVER-AP]]></article-title>
<source><![CDATA[Aten Primaria. 1 de junio de]]></source>
<year>2018</year>
<volume>50</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>359-67</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
<name>
<surname><![CDATA[Tse]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation]]></article-title>
<source><![CDATA[Lancet Lond Engl.]]></source>
<year>2012</year>
<volume>379</volume>
<numero>9816</numero>
<issue>9816</issue>
<page-range>648-61</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guevara]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[LAC]]></given-names>
</name>
<name>
<surname><![CDATA[Calzado]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Marrero]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo en complicaciones tromboembólicas cerebrales de pacientes con fibrilación auricular permanente no valvular]]></article-title>
<source><![CDATA[Rev Inf Científica]]></source>
<year>2019</year>
<volume>98</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-87</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shinohara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fujino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Akitsu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Koike]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation]]></article-title>
<source><![CDATA[J Cardiol]]></source>
<year>2019</year>
<volume>73</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-13</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<source><![CDATA[Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score - PubMed]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
